Hypertension prevalence and Framinghamrisk score stratification in a largeHIV-positive cohort inUganda

Journal of Hypertension

Volumn 31, Issue 7, 2013, Pages 1372-1378

  Mateen, Farrah J ^a   Kanters, Steve ^b,c   Kalyesubula, Robert ^d   Mukasa, Barbara ^e   Kawuma, Esther ^e   Kengne, Andre P ^f   Mills, Edward J ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MAKERERE UNIVERSITY   (Uganda)

^e MILDMAY UGANDA   (Uganda)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Blood pressure; Cholesterol; Framingham risk score; HIV; Hypertension; Uganda

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TUBERCULOSIS; UGANDA; BLOOD; BLOOD PRESSURE; COHORT ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; YOUNG ADULT; COMPLICATION;

ADOLESCENT; ADULT; BLOOD PRESSURE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS; UGANDA; YOUNG ADULT;

EID: 84880042692     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328360de1c     Document Type: Article

References (36)

1. World Health Organization. World Health Statistics (2012). http://www.who.int/gho/publications/world-health-statistics/2012/en/index.html [Accessed 20 October 2012].
2. Cattelan A, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS 2001; 15:805-807.
3. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953-960.
4. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-nai?ve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22:731-736.
5. Barnighausen T, Welz T, Hosegood V, Batzing-Feigenbaum J, Tanser F, Herbst K, et al. Hiding in the shadows of the HIV epidemic: obesity and hypertension in a rural population with very high HIV prevalence in South Africa. J Hum Hypertens 2008; 22:236-239.
6. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, et al. and the SEARCH Collaboration. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLos One 2012; 7:e43400.
7. Manner IW, Baekken M, Oektedalen O, Os I. Hypertension and antihypertensive treatment in HIV-positive individuals. A longitudinal cohort study. Blood Press 2012; 21:311-319.
8. Tomaszewski R. Cardiomegaly in tropical Africa. Int Marit Health 2012; 63:56-58.
9. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012; 172:1386-1394.
10. Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Vander Stichele R, Van Bortel LM. Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens 2011; 29:1243-1252.
11. Funk A, Kanters S, Nansubuga M, Mwehire D, Featherstone A, Druyts E, et al. Cohort profile: the MUg observational cohort. Int J Epidemiol 2012; 41:1594.
12. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MH, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part I: Blood pressure in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-3161.
13. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
14. National Institutes of Health. National Heart, Lung, and Blood Institute. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. National Cholesterol Education Program. NIH Publication No. 02-5215. Bethesda, MD: National Institutes of Health; September 2002.
15. United Nations Department of Economic and Social Affairs. World Population Prospects, the 2010 Revision. http://esa.un.org/unpd/wpp/Excel-Data/ population.htm [Accessed 10 November 2012].
16. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363-2369.
17. Betoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB. Implications of new hypertension guidelines in the United States. Hypertension 2012; 60:639-644.
18. Ong KL, Cheung M, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
19. Maher D, Waswa L, Baisley K, Karabarinde A, Unwin N. Epidemiology of hypertension in low-income countries: a cross-sectional populationbased survey in rural Uganda. J Hypertens 2011; 29:1061-1068.
20. Scholten F, Mugisha J, Seeley J, Kinyanda E, Nabubukwa S, Kowal P, et al. Health and functional status among older people with HIV/AIDS in Uganda. BMC Publ Health 2011; 11:886.
21. Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, Kimaiyo S. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLos One 2011; 6:e22288.
22. Fisher SD, Kanda BS, Miller TL, Lipshultz SE. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIVinfected patients. Am J Cardiovasc Drugs 2011; 11:383-394.
23. Lipshultz SE, Mas CM, Henkel JM, Franco VI, Fisher SD, Miller TL. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev Anti Infect Ther 2012; 10:661-674.
24. Hasumi T, Jacobsen KH. Hypertension in South African adults: results of a nationwide survey. J Hypertens 2012; 30:2098-2104.
25. Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Intl Assoc Phys AIDS Care (Chic) 2012; 11:20-25.
26. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753.
27. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus nonlaboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008; 371:923-931.
28. Namusisi O, Sekandi JN, Kasasa S, Wasswa P, Kamara NT, Bitekyerezo M, et al. Risk factors for noncommunicable diseases in rural Uganda: a pilot surveillance project among diabetes patients at a referral hospital clinic. Pan Afr Med J 2011; 10:47.
29. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in U.S. adults: findings from the National Health and Nutrition Examination Survey 2003 to 2008. Circ Cardiovasc Qual Outcomes 2010; 3:8-14.
30. Jeemon P, Prabhakaran D, Huffman MD, Ramakrishnan L, Goenka S, Thankappan KR, et al. on behalf of the Sentinel Surveillance in Industrial Populations Study Group. Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). BMJ Open 2011; 1:e000068.
31. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23:625-630.
32. Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S, Barahona I, Brodine S. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS 2010; 24:353-360.
33. Kaddumukasa M, Ddumba E, Duncan P, Goldstein LB. Poststroke hypertension in Africa. Stroke 2012; 43:3402-3404.
34. Rabkin M, El-Sadr WM. Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront noncommunicable diseases. Glob Public Health 2011; 6:247-256.
35. Ordunez-Garcia P, Bernal Munoz JL, Pedraza D, Espinosa-Brito A, Silva LC, Cooper RS. Success in control of hypertension in a low-resource setting: the Cuban experience. J Hypertens 2006; 24:845-849.
36. Janssens B, Van Damme W, Raleigh B, Gupta J, Khem S, Soy Ty K, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia. Bull World Health Organ 2007; 85:880-885.